Short answer
Inhibrx Biosciences, Inc. (INBX) filed its Q3 2025 10-Q quarterly report on Nov 14, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$35M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- −100.0% QoQ
- Net income
- −$35M
- +19.6% YoY · −23.0% QoQ
- EPS (diluted)
- −$2.28
- +59.7% YoY · −23.2% QoQ
Source: XBRL data from the Inhibrx Biosciences, Inc. (INBX) Q3 2025 10-Q on SEC EDGAR. USD.
Inhibrx Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly emphasized monetization risk: ozekibart transaction may fail to close or deliver anticipated stockholder value
- Operational risk: transaction process could distract management and disrupt business operations
- Market risk: perceived transaction delays or failure could depress common-stock price and restrict capital-market access
- Financial risk: transaction costs and expenses could exceed expectations
- Tax risk: monetization transaction may not achieve desired tax efficiency
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibrx Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.